FindTrial
Sign In

A Study on Antibody Levels in Fingertip-Derived Dried Blood Spots

Monitoring and Analysis of Infectious Disease Immune Protection Markers in Fingertip-Derived Dried Blood Spots

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114489
Enrollment
Unknown
Registered
2025-12-12
Start date
2024-12-05
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Common respiratory infectious diseases such as COVID-19 and influenza A

Interventions

Observation group:N/A

Sponsors

Shenzhen Luohu People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. Had a respiratory infection (cold-like symptoms) within one year and has complete clinical data; 2. Patients between the ages of 3 and 60.

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1.Autoimmune diseases; 2.Primary or secondary immunodeficiencies; 3.Malignant tumors.

Design outcomes

Primary

MeasureTime frame
SARS-CoV-2 Wild-Type (WT) Spike Protein RBD-Specific IgG Binding Antibody;SARS-CoV-2 Wild-Type (WT) Full-Length Spike (S) Protein Trimer-Specific IgG Binding Antibody;SARS-CoV-2 KP.3 Variant Spike (S) Protein RBD-Specific IgG Binding Antibody;Influenza A Virus H1 Subtype Hemagglutinin (HA) Protein Full-Length Trimer-Specific IgG Binding Antibody;Influenza A Virus H3 Subtype Hemagglutinin (HA) Protein Full-Length Trimer-Specific IgG Binding Antibody;Influenza B Virus Hemagglutinin (HA) Protein Full-Length Trimer-Specific IgG Binding Antibody;—

Countries

China

Contacts

Public ContactHongmei Mo

Shenzhen Luohu People's Hospital

437897734@qq.com+86 136 7010 0176

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026